Upstate Carolina Community Clinical Oncology Program

卡罗莱纳州北部社区临床肿瘤学计划

• 批准号: 6910000
• 负责人: James D Bearden
• 金额: $ 173.37万
• 依托单位: SPARTANBURG REGIONAL MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-09-01 至 2007-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6910000
• 关键词: breast neoplasms; cancer prevention; clinical research; cooperative study; ethnic group; human subject; longitudinal human study; neoplasm /cancer diagnosis; neoplasm /cancer education; neoplasm /cancer therapy; oncology; prostate neoplasms; quality of life

DESCRIPTION: (Applicant?s Description) Building on 17 years of experience as a CCOP, the Upstate Carolina Community Clinical Oncology Program (UC-CCOP) seeks the opportunity to continue to meet our community?s need for innovative and relevant studies of promising therapeutic modalities and cancer control research through the Year 2006. The program was re-named in 1998, previously known as Spartanburg CCOP. The CCOP provides access to national cooperative clinical trials to well over 800,000 people in 9 counties: 6 in South Carolina and 3 in North Carolina. SC is 21st in population density and ranks 14th in the percent who are medically underserved. The registries report over 2000 new cancer patients per year, nearly doubled since 1995. Against this rural background, a five hospital consortium was developed for the conduct of community clinical trials. The service area has a 17.4% minority base. Unique capacities are demonstrated in minority accrual (over 22% in treatment & ranking high in cancer control) and by accruing the underserved: 99 entries in the last 5 years. The CCOP brings together the strength and resources of multidisciplinary investigators who collaborate in the conduct of studies from SWOG, NSABP, RTOG, GOG, MDACC, and Cancer Center at Wake Forest University. The 81 investigators include 19 oncologists along with 62 colleagues in other disciplines. The UC-CCOP has contributed over 3000 entries to clinical trials since 1983, the start of the CCOP program. Over the next five years, the overall aim is to reduce cancer incidence, morbidity, and mortality by accelerating the transfer of newly developed cancer prevention, early detection, treatment, patient management, rehabilitation, and continuing care technology to widespread community application, including special emphasis on patient management trials, an emphasis on trials exploring the use of complementary medicine, and continued attention to Quality of Life research. By careful design, the program will focus our resources on cancer control research while continuing to build our treatment program. These complementary objectives of both treatment and cancer control are a ready match for the patient population and fit within CCOP interests and capabilities. A rural outreach program has been initiated and will continue to grow. The immediate goals of the CCOP are to continue to increase our accrual; to maintain wide community participation, including minority groups and underserved populations, in both treatment and cancer control research approved by NCI; to sustain and continue to expand our very large cancer control program, including the use of a range of resources to identify potential candidates for cancer control research projects. To maintain Follow-Up to the Breast Cancer Prevention Trial (BCPT), the Prostate Cancer Prevention Trial (PCPT), to increase accrual to STAR trial and others, and to initiate the upcoming SELECT Trial are primary objectives. In summary, the CCOP track record demonstrates the ability to manage complex clinical research and cancer control activities while producing the highest quality data. The CCOP has the facilities and well-trained professional personnel to support the full array of studies. The CCOP staffing pattern, protocol management procedures, patient/participant management approaches, quality control mechanisms, IRB structure and liaison are all in place and functioning to support current and future therapeutic and cancer control activities. In the first year of new funding (2001-2002), we will 1) contribute nearly 600 credits to the National Cancer Institute?s Community Clinical Oncology Program: over 118 treatment credits and over 475 cancer control credits and 2) will serve the Carolinas as a nationally recognized research program of excellence.

描述：（申请人？s描述）基于17年的经验， a CCOP，上州卡罗莱纳社区临床肿瘤学项目（UC-CCOP） 寻求机会继续与我们的社区接触需要创新 以及有希望的治疗方式和癌症控制的相关研究 研究到2006年。该计划于1998年重新命名， 也就是斯帕坦堡CCOP CCOP提供国家合作社 在9个县进行了超过80万人的临床试验：南部6个县 卡罗莱纳州和3个在北卡罗来纳州州。SC在人口密度和排名方面排名第21位 在医疗服务不足的人群中排名第14。登记处报告说 每年新增2000名癌症患者，自1995年以来几乎翻了一番。反对这个 农村背景下，一个五医院财团的发展进行， 社区临床试验。服务区有17.4%的少数民族。 独特的能力体现在少数应计费用（治疗费用超过22 和癌症控制排名靠前），并通过积累服务不足：99项 在过去的五年里。CCOP汇集了以下方面的力量和资源： 多学科研究者，他们合作进行研究， SWOG、NSABP、RTOG、GOG、MDACC和维克森林大学癌症中心。 81名研究者包括19名肿瘤学家沿着62名同事， 学科UC-CCOP已经为临床试验贡献了3000多个条目 自1983年以来，CCOP计划的开始。在接下来的五年里， 总体目标是通过以下措施降低癌症发病率、发病率和死亡率： 加快转移新开发的癌症预防，早期 检测、治疗、患者管理、康复和持续护理 技术，以广泛的社区应用，包括特别强调 患者管理试验，重点是探索使用 补充医学，并继续关注生活质量研究。 通过精心设计，该计划将把我们的资源集中在癌症控制上 研究，同时继续建立我们的治疗方案。这些互补 治疗和癌症控制的目标是一个现成的匹配， 患者人群，并符合CCOP的利益和能力。一个农村 外联方案已经启动，并将继续扩大。立即 CCOP的目标是继续增加我们的应计费用;保持广泛的 社区参与，包括少数群体和得不到充分服务的群体 在NCI批准的治疗和癌症控制研究中; 维持并继续扩大我们庞大的癌症控制计划， 包括利用一系列资源来确定潜在的候选人， 癌症控制研究项目。维持对乳腺癌的随访 预防试验（BCPT），前列腺癌预防试验（PCPT） 增加对星星试验和其他试验的应计费用，并启动即将到来的SELECT 试验是主要目的。总之，CCOP的跟踪记录表明， 管理复杂的临床研究和癌症控制活动的能力 同时产生最高质量的数据。CCOP拥有设施和 训练有素的专业人员，以支持全面的研究。的 CCOP人员配置模式、方案管理程序、患者/参与者 管理方法、质量控制机制、IRB结构和联络 都到位并发挥作用，以支持当前和未来的治疗和 癌症控制活动。在提供新资金的第一年（2001-2002年）， 将1）向国家癌症研究所捐赠近600个学分？S 社区临床肿瘤学计划：超过118个治疗学分和超过475个 癌症控制信贷和2）将作为一个全国性的 公认的卓越研究计划。